Ipamorelin vs Sermorelin

Side-by-side comparison of evidence, mechanisms, dosing, safety, and regulatory status.

Ipamorelin: DSermorelin: C

Attribute	Ipamorelin	Sermorelin
Category	Growth Hormone Secretagogue	Growth Hormone Secretagogue
Evidence Rating	D — Preclinical	C — Phase I–II Clinical Trials
Clinical Status	Research-only / Not approved for human use	Previously FDA-approved (Geref, discontinued); now used off-label via compounding
Mechanism	Ipamorelin (sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2) selectively binds to the Growth Hormone Secretagogue Receptor (GHS-R1a) on anterior pituitary somatotroph cells, increasing cAMP and activating protein kinase A to promote pulsatile GH secretion. Its structural specificity means it fits only the GH...	Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both transcription of the HGH gene and pulsatile release of endogenous growth hormone. The released HGH increases protein synthesis, fat breakdown (lipolysis), and tissue repair across multip...
Half-Life	~2 hours	~10–20 minutes
Bioavailability	High SC bioavailability	—
Molecular Weight	~711.9 g/mol	~3357.9 g/mol
WADA Status	Prohibited	Prohibited
Dosing	100–300 mcg per injection, 2–3x daily, 2–3 times daily (typically before meals and before bed) (Subcutaneous)	100–300 mcg/day SC, Once daily (typically before bed) (Subcutaneous)
Key Use Cases	Anti-Aging Body Composition Sleep	Anti-Aging Body Composition Sleep
Safety Concerns	Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours Common: mild temporary "head rush" or flushing immediately after injection due to sudden vasodilation	Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) Systemic: headaches, nausea, dizziness, facial flushing, drowsiness (mild, transient, usually in initial weeks as the body adjusts)
Contraindications	Active malignancy or personal/family history of cancer (GH promotes cell proliferation) Pregnancy and breastfeeding Pituitary disorders or prior pituitary surgery Diabetes with retinopathy (GH can affect blood glucose and worsen retinopathy)	Active malignancy or active cancer (GH promotes cell proliferation) Pregnancy and breastfeeding Pituitary disorders or prior pituitary surgery Uncontrolled diabetes, severe sleep apnea, or untreated hypertension
Regulatory (US)	Not FDA-approved. Research chemical only. WADA-banned (S2 growth factor).	Previously FDA-approved (Geref) for pediatric GH deficiency; voluntarily discontinued by manufacturer for commercial reasons. FDA confirmed in 2013 it was not withdrawn for safety. Available via compounding pharmacies. WADA-banned.

Shop Ipamorelin

View Ipamorelin Product

Shop Sermorelin

View Sermorelin Product

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

All Comparisons Browse Catalog

Ipamorelin vs Sermorelin

Explore MoreComparisons

Your Cart

Explore More
Comparisons